| Public Citizen slams rivaroxaban and ROCKET-AF - Cardiovascular Business |
|
|
Cardiovascular Business Despite receiving praise from the FDA's Cardiovascular and Renal Drug Advisory Committee, the anticoagulant rivaroxaban (Xarelto, Bayer/Johnson & Johnson) is now getting scrutiny from Public Citizen. In a letter dated Oct. 20 and sent to the FDA, |